Janux Therapeutics (JANX) Operating Leases (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Operating Leases data on file, last reported at $19.1 million in Q1 2026.

• On a quarterly basis, Operating Leases fell 8.18% year-over-year to $19.1 million in Q1 2026; TTM through Mar 2026 was $19.1 million, a 8.18% decrease from a year earlier, with the FY2025 full-year figure at $19.7 million, down 7.19% from the prior year.
• Operating Leases for Q1 2026 stood at $19.1 million, down from $19.7 million in the prior quarter.
• Over the last five years, Operating Leases for JANX reached as high as $24.5 million in Q4 2022 and fell as low as $19.1 million in Q1 2026.
• Historically, Operating Leases has averaged $22.2 million across 5 years, with a median of $22.4 million in 2024.
• Across the five-year window, Operating Leases jumped 104647.83% in 2022 and fell 8.44% in 2025, its largest moves.
• Year by year, Operating Leases stood at $24.5 million in 2022, then retreated by 6.18% to $23.0 million in 2023, then retreated by 7.6% to $21.3 million in 2024, then fell by 7.19% to $19.7 million in 2025, then dropped by 3.28% to $19.1 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $19.1 million in Q1 2026, $19.7 million in Q4 2025, and $20.4 million in Q3 2025.